Background N-Formyl-methionylleucyl-phenylalanine (FMLP) is a bacterial oligopeptide which stimulates neutrophil chemotaxis, degranulation and superoxide generation. Inhalation of FMLP produces bronchoconstriction in man; in the rabbit this is in part neutrophil dependent. The effects of inhalation of FMLP on peripheral blood leucocytes in normal subjects has been studied. Methods This was an open study in non-asthmatic subjects. Change in total peripheral white cell count were studied for 15 minutes after inhalation of 04 umol FMLP in six subjects. Change in total and differential white cell count and spontaneous neutrophil chemiluminescence were then studied five and 30 minutes after inhalation of 0 4 pmol FMLP (n = 7) or diluent (n = 4). Finally, leucocytes from three subjects were labelled ex vivo with technetium-99m labelled sulphur colloid and reinfused. The effect of inhalation of FMLP or diluent on pulmonary neutrophil flux was studied by continuous gamma scanning of a pulmonary window. Results Leucopenia occurs rapidly after inhalation of FMLP, the nadir of the white cell count (53% of baseline) occurring at four minutes. This was followed by a rebound increase in white cell count evident at 15 minutes (154% of baseline). Five 
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STUDY 2
Neutropenia and monocytopenia were seen five minutes after FMLP inhalation. The mean (SE) neutrophil count and monocyte count were both significantly reduced, the neutrophil count to 0-57(0-21) x 109/1 (17% of baseline) and the monocyte count to 0 24(0 08) x 109/1 (40% of baseline). At this time the eosinophil count was 26% of baseline (0 05 < p < 0-1). At 30 minutes after FMLP, the neutrophil count was significantly elevated to 7-30(1{02) x 109/1 (213% of baseline) and the monocyte count had returned to 0-73(0-13) x 109/1 (124% of baseline). The eosinophil count was now, however, significantly reduced at 0-03(0 02) x 109/1 (24% of baseline) (figure 2).
All seven subjects became transiently neutropenic and five exhibited facial flushing. There was no change in leucocyte count after DMSO. Five minutes after FMLP inhalation, coincident with neutropenia, chemiluminescence was significantly increased to 186% (34%) of baseline. Thirty minutes after FMLP, chemiluminescence had returned to a normal level of 82 cpm (43% of baseline). There was no change in chemiluminescence after DMSO inhalation. STUDY 3 Loss of activity over the lungs was biphasic. There was an initial phase of rapid activity decay with a half life of about 5 minutes. Pretreatment activity half life was calculated for the 20 minutes before FMLP or DMSO inhalation to allow five half lives of the early rapid phase to elapse for measurement of pretreatment half life. There was considerable within and between subject variability in the pretreatment half life, but no increase in lung activity during the period of neutropenia. Over the 30 minutes of the study, FMLP inhalation caused a marked increase in the half life of activity in the lung fields in two subjects and an increase in lung activity in the third (table) .
Discussion
In this study inhalation of FMLP activated circulating neutrophils and produced transient neutropenia and monocytopenia and a more prolonged eosinopenia. Neutropenia was followed by neutrophilia which lasted for more than four hours. During the phase of neutrophil leucocytosis, neutrophils were retained within the lungs.
Neutrophils were activated at the time of neutropenia, as measured by increased chemiluminescence activity in unstimulated cells, but the activation was transient. The separation of red blood cells from the leucocyte fraction avoided centrifugation with its inevitable neutrophil activation. However, with this method, separation of red cells took about 25 minutes and counting therefore occurred about 30 minutes after the FMLP stimulus. Because of this delay between FMLP stimulus and counting, and because activated neutrophils tend to be marginated in the lungs or elsewhere, the observed increase in chemiluminescence may have substantially underestimated the total degree of neutrophil activation in the peripheral blood and could not measure activation occurring in the tissues.
The mechanisms responsible for FMLP induced monocytopenia are probably similar to those for neutrophils, as exposure to chemotactic factors in vivo produces monocyte adherence and extravascular migration in a similar fashion to that seen with neutrophils.20 The flushing response was consistently associated with neutropenia, although neutropenia did occur without flushing in one subject. When incremental doses of FMLP are administered by inhalation, flushing is seen after the first dose or not at all.6'2 Bronchoconstriction may occur with this dose, a higher dose or not at all, implying that the mechanisms producing neutropenia and flushing may be unrelated to those which produce decrements in airway function.
The effects of inhaled FMLP and inhaled platelet activating factor show some similarities and some differences.27 Both produce flushing, activate neutrophils and produce transient neutropenia followed by rebound neutrophilia. Platelet activating factor inhalation had no effect on circulating eosinophil count whereas FMLP produced significant eosinopenia, an interesting finding since, of the two agents, platelet activating factor is generally regarded as more eosinophil specific. Bronchoalveolar lavage neutrophils are elevated whereas four hours after inhalation of platelet activating factor neutrophils are retained in the lung after FMLP over a shorter period.
Thus FMLP inhalation activates circulating neutrophils and produces transient neutropenia, monocytopenia and more prolonged eosinopenia. Over a longer period neutrophil retention is seen in the lung. These findings may be relevant to the accumulation of leucocytes within the lung during bacterial bronchial infection.
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